Australia markets closed

Nurix Therapeutics, Inc. (NRIX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
18.93-1.98 (-9.47%)
At close: 04:00PM EDT
18.70 -0.23 (-1.22%)
After hours: 06:06PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
30/11/2023
30/11/2022
30/11/2021
30/11/2020
30/11/2019
Cash flows from operating activities
Net income
-144,733
-143,948
-180,360
-117,194
-43,242
-
Depreciation & amortisation
14,362
13,654
10,808
6,082
2,180
-
Stock-based compensation
33,014
33,673
28,131
15,800
4,301
-
Change in working capital
28,526
20,121
-19,022
9,113
36,408
-
Accounts receivable
-
0
6,000
-6,000
0
-
Accounts payable
284
1,614
85
1,589
1,234
-
Other working capital
-83,872
-89,766
-172,051
-90,026
-4,633
-
Other non-cash items
-
-
201
-
-
-
Net cash provided by operating activities
-74,864
-81,365
-159,807
-84,365
-80
-
Cash flows from investing activities
Investments in property, plant and equipment
-9,008
-8,401
-12,244
-5,661
-4,553
-
Purchases of investments
-278,495
-246,334
-239,366
-348,497
-275,224
-
Sales/maturities of investments
375,249
323,036
278,808
245,907
25,373
-
Net cash used for investing activities
87,746
68,301
27,198
-108,251
-254,404
-
Cash flows from financing activities
Common stock issued
-
0
19,400
150,157
218,147
-
Other financing activities
-
-
-
-
-7
-16
Net cash used provided by (used for) financing activities
3,360
3,217
117,192
153,882
339,024
-
Net change in cash
16,242
-9,847
-15,417
-38,734
84,540
-
Cash at beginning of period
34,472
65,375
80,792
119,526
34,986
-
Cash at end of period
50,714
55,528
65,375
80,792
119,526
-
Free cash flow
Operating cash flow
-74,864
-81,365
-159,807
-84,365
-80
-
Capital expenditure
-9,008
-8,401
-12,244
-5,661
-4,553
-
Free cash flow
-83,872
-89,766
-172,051
-90,026
-4,633
-